Publications
You can refine your search results by using the keyword search function.
| Publication date (year/month/day) |
Title | Keywords | Authors | Journal |
|---|---|---|---|---|
| 2025-04-01 | solid drug nanoparticles, niclosamide, nitazoxanide | RSC Pharmaceutics | ||
| 2024-11-15 | hepatitis C virus, community survey, LMICs. | Furl, R., Scarsi, K.K., Sayles, H., Anderson, M., Dountio Ofimboudem, J., Weld, E.D., Waked, I., Gomaa, A., Al-Khatib, A., Elshobary, F.M., Desalegn, H., Fisseha, H., Solomon, S., Mehta, S., Owen, A., Rannard, S., Thomas, D.L., & Swindells, S. | Journal of Viral Hepatitis | |
| 2024-03-28 | hepatitis C virus, community survey, LMICs. | Gupta, N., Swindells, S., Scarsi, K.K., Furl, R., Thomas, D.L., Weld, E.D., Dountio Ofimboudem, J., Desalegn, H., Hamid, S., de la Torre Rosasa, A., Miranda, A.E., Owen, A., Rannard, S., Hiebert, L., Sun, K., & Ward, J.W. | Journal of Viral Hepatitis | |
| 2023-11-30 | Physiologically based pharmacokinetic modelling of cabotegravir microarray patches in rats and humans | HIV, cabotegravir, antiretroviral, microarray patches | Kinvig, H., Rajoli, R.K.R., Pertinez, H., Vora, L.K., Volpe-Zanutto, F., Donnelly, R., Rannard, S., Flexner, C., Siccardi, M., & Owen, A. | Pharmaceutics |
| 2023-11-23 | Lack of antiviral activity of probenecid in vitro and in Syrian golden hamsters | sars-cov-2, antiviral | Box, H.J., Sharp, J., Pennington, S.H., Kijak, E., Tatham, L., Caygill, C.H., Lopeman, R.C., Jeffreys, L.N., Herriott, J., Neary, M., Valentijn, A., Pertinez, H., Curley, P., Arshad, U,. Rajoli, R.K.R., Jochmans, D., Vangeel, L., Neyts, J., Chatelain, E., Escudié, F., Scandale, I., Rannard, S., Stewart, J.P., Biagini, G.A., & Owen, A. | Journal of Antimicrobial Chemotherapy |
| 2023-10-27 | Chemoprophylactic assessment of combined intranasal SARS-CoV-2 polymerase and exonuclease inhibition in syrian golden hamsters | sars-cov-2 | Gallardo-Toledo, E., Neary, M., Sharp, J., Herriott, J., Kijak, E., Bramwell, C., Curley, P., Arshad, U., Pertinez, H., Rajoli, R.K.R., Valentijn, A., Cox, H., Tatham, L., Kipar, A., Stewart, J., & Owen, A. | Viruses |
| 2023-10-25 | Development and validation of a liquid chromatographic-tandem mass spectrometric assay for the quantification of the direct acting antivirals glecaprevir and pibrentasvir in plasma | hepatitis C virus, glecaprevir, pibrenstasvir | Garza, K.Y., Pandey, A., & Marzinke, M.A. | Journal of Pharmaceutical and Biomedical Analysis |
| 2023-10-13 | An open label, adaptive, phase 1 trial of high‐dose oral nitazoxanide in healthy volunteers: An antiviral candidate for SARS‐CoV‐2 | sars-cov-2, nitazoxanide, antiviral | Walker, L.E., FitzGerald, R., Saunders, G., Lyon, R., Fisher, M., Martin, K., Eberhart, I., Woods, C., Ewings, S., Hale, C., Rajoli, R.K.R., Else, L., Dilly-Penchala, S., Amara, A., Lalloo, D.G., Jacobs, M., Pertinez, H., Hatchard, P., Waugh, R., Lawrence, M., Johnson, L., Fines, K., Reynolds, H., Rowland, T., Crook, R., Okenyi, E., Byrne, K., Mozgunov, P., Jaki, T., Khoo, S., Owen, A., Griffiths, G., & Fletcher, T.E. | Clinical Pharmacology & Therapeutics |
| 2023-10-12 | Clinically relevant atovaquone-resistant human malaria parasites fail to transmit by mosquito | malaria, atovaquone | Balta, V.A., Stiffler, D., Sayeed, A., Tripathi, A.K., Elahi, R., Mlambo, G., Bakshi, R.P., Dziedzic, A.G., Jedlicka, A.E., Nenortas, E., Romero-Rodriguez, K., Canonizado, M.A., Mann, A., Owen, A., Sullivan, D.J. Prigge, S.T., Sinnis, P., & Shapiro, T.A. | Nature Communications |
| 2023-08-21 | Preferences of patients and providers in high-burden malaria settings for long-acting malaria chemoprevention | malaria, survey | Scarsi, K.K., Sayles, H., Kapungu, K., Sifuna, P., Ippolito, M.M., Furl, R., Anderson, M.J., Dountio Ofimboudem, J., Chongwe, G., Hutter, J., Rannard, S., Owen, A., & Swindells, S. | The American Journal of Tropical Medicine and Hygiene |
| 2023-08-15 | Evaluation of nafamostat as chemoprophylaxis for SARS-CoV-2 infection in hamsters | nafamostat, sars-cov-2 | Neary, M., Sharp, J., Gallardo-Toledo, E., Herriott, J., Kijak, E., Bramwell, C., Cox, H., Tatham, L., Box, H., Curley, P., Ashad, U., Rajoli, R.K.R, Pertinez, H., Valentijn, A., Dhaliwal, K., Mc Caughan, F., Hobson, J., Rannard, S., Kipar, A., Stewart, J., & Owen, A. | Viruses |
| 2023-06-14 | Using dynamic oral dosing of rifapentine and rifabutin to simulate exposure profiles of long-acting formulations in a mouse model of tuberculosis preventive therapy | tuberculosis, rifapentine, rifabutin | Chang, Y.S., Li, S.Y., Pertinez, H., Betoudji, F., Lee, J., Rannard, S., Owen, A., Nuermberger, E.L., & Ammerman, N.C. | Antimicrobial Agents and Chemotherapy |
| 2023-03-09 | Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV-2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use case | Ronapreve, sars-cov-2 | Tatham, L., Kipar, A., Sharp, J., Kijak, E., Herriott, J., Neary, M., Box, H., Gallardo Toledo, E., Valentijn, A., Cox, H., Pertinez, H., Curley, P., Arshad, U., Rajoli, R.K., Rannard, S., Stewart, J., & Owen, A. | bioRxiv |
| 2022-12-05 | FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2 | fxr inhibitor, sars-cov-2, ace2 | Brevini, T., Maes, M., Webb, G. J., John, B. V., Fuchs, C. D., Buescher, G., & Sampaziotis, F. | Nature |
| 2022-11-21 | Prospects for long-acting treatments for hepatitis C | hepatitis C virus | Thomas, D. L., Owen, A., & Kiser, J. J. | Clinical Infectious Diseases |
Subscribe to the LONGEVITY newsletter
Any personal information you provide will be held in accordance with The EU General Data Protection Regulation (GDPR). For more information please see our Privacy notice.
Our funding
The LONGEVITY Project is funded by Unitaid
The project also involves critical partners and collaborators in the Clinton Health Access Initiative, Johns Hopkins University, Medicines Patent Pool, Tandem Nano Ltd., Treatment Action Group and the University of Nebraska Medical Center.
